Home > Insider Trading > Filing (0001213900-17-012851)

Filing Details

Accession Number:: 0001213900-17-012851
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-12-01 16:25:01
Reporting Period:: 2017-11-29

Accepted Time:: 2017-12-01 16:25:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
812796	Soligenix Inc.	SNGX	Pharmaceutical Preparations (2834)	411505029

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1092601	Spa Essetifin	Via Sudafrica, 20 Rome L6 00144	No	No	No	Yes
1163608	Paolo Cavazza	Via Tesserete, 10 Lugano V8 00000	No	No	No	Yes
1385625	Leadiant Biosciences, Inc.	9841 Washingtonian Blvd., Suite 500 Gaithersburg MD 20878	No	No	No	Yes
1525742	Francesca Cavazza	Via Sudafrica, 20 Rome L6 00144	No	No	No	Yes
1525743	Silvia Cavazza	Via Sudafrica, 20 Rome L6 00144	No	No	No	Yes
1525744	Enrico Cavazza	Via Sudafrica, 20 Rome L6 00144	No	No	No	Yes
1718557	Martina Preta Cavazza	Via Sudafrica, 20 Rome L6 00144	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-11-29	271,140	$2.12	0	No	4	S	Indirect	Indirect
Common Stock	Acquisiton	2017-11-29	271,140	$2.12	271,140	No	4	P	Direct
Common Stock	Disposition	2017-11-29	5,954	$2.12	0	No	4	S	Indirect	Indirect
Common Stock	Acquisiton	2017-11-29	5,954	$2.12	277,094	No	4	P	Direct
Common Stock	Disposition	2017-11-29	16,416	$2.12	0	No	4	S	Indirect	Indirect
Common Stock	Acquisiton	2017-11-29	16,416	$2.12	293,510	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Indirect
No	4	P	Direct
No	4	S	Indirect	Indirect
No	4	P	Direct
No	4	S	Indirect	Indirect
No	4	P	Direct

Footnotes

Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split.
This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer.
Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock.
Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin.
Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin.
Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein.